Metraipolis › archive › dc_9fd8eb251f45

The infectious diseases clinical research program acute respiratory infection repository protocol: Opportunities to understand current and future epidemics — Europe PMC PMID:40700358

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40700358
DOI
10.1371/journal.pone.0317065
License (as archived)
CC0-1.0
Archived
2026-10-06T09:44:55.754Z
SHA-256 of the archived text
33b9675f65d48af424ea6d8c786174c7270f290970862f42c0bdc226de738c36
Stable URL of this page
https://metraipolis.com/documento/dc_9fd8eb251f45

How to cite

The infectious diseases clinical research program acute respiratory infection repository protocol: Opportunities to understand current and future epidemics — Europe PMC PMID:40700358 — Europe PMC (en), https://europepmc.org/article/MED/40700358 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_9fd8eb251f45 (Metraipolis archive dc_9fd8eb251f45, sha256 33b9675f65d48af424ea6d8c786174c7270f290970862f42c0bdc226de738c36)
BibTeX
@misc{dc9fd8eb251f45,
  title = {The infectious diseases clinical research program acute respiratory infection repository protocol: Opportunities to understand current and future epidemics — Europe PMC PMID:40700358},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40700358},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_9fd8eb251f45; sha256 33b9675f65d48af424ea6d8c786174c7270f290970862f42c0bdc226de738c36},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/40700358. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Acute respiratory infections (ARI) are a major cause of morbidity and lost workdays in both military and non-military populations. To better understand these infections and their outcomes, the Infectious Diseases Clinical Research Program has enabled nine major ARI clinical research protocols in the last decade, including observational studies and trials, spanning emerging and reemerging ARI threats including Severe Acute Respiratory Syndrome Coronavirus 2, influenza, adenovirus, entero/rhinovirus, human metapneumovirus, respiratory syncytial virus, and other pathogens. These protocols have resulted in epidemiological, clinical and laboratory data and biospecimens from over 26,000 participants, most of whom were beneficiaries of a geographically distributed Military Health System. Methods: The Acute Respiratory Infection Repository Protocol establishes a unique Department of Defense (DoD) research resource through the pooling of data and specimens from nine ARI protocols into a master, standardized database with a linked specimen repository. This will enable further targeted scientific questions in participant-level pooled meta-analyses and will serve as an on-demand repository for rapid assay development, sample size estimations for prospective studies, and observational study/clinical trial design (including as part of future rapid pandemic research response). Accordingly, the objectives and study design of this protocol are broad. This protocol will allow analyses on outcomes including: (i) short-term ARI outcomes such as hospitalization, work days lost, symptom severity and duration; (ii) post-acute ARI outcomes, including persistence of symptoms, return-to-health, post-ARI medical encounters; (iii) vaccine effectiveness for Coronavirus disease 2019 (COVID-19), influenza, and adenovirus vaccines; (iv) ARI infection and vaccination elicited immune responses (humoral, T-cell, other); (v) therapeutic effectiveness of COVID-19 and influenza antivirals (acute symptoms, hospitalization, post-acute sequelae); (vi) effectiveness of non-pharmaceutical interventions (e.g., masking) against infection; (vii) prognostic and mechanistic host viral biomarkers which correlate with the above outcomes; (viii) ARI diagnostic assay validity and performance. This repository protocol is inherently broad in scope; the collation of standardized data and phenotype-linked specimens is a fundamental, primary objective. Discussion: This protocol will support statistical and laboratory analyses, including activities related to rapid epidemic response such as assay development and rapid sample size calculations for clinical trials. A series of more specific scientific questions from current and future collaborators will leverage this joint database and specimen repository; these questions will target important aspects of ARI infection, transmission, outcomes, and treatment. Future protocols (and ongoing data from existing IDCRP protocols) will be added to this collaborative repository protocol.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2025 (prima pubblicazione 2025-07-23).
Identificativi: PMID 40700358 · PMCID PMC12286355 · DOI 10.1371/journal.pone.0317065.
Descrittori MeSH principali: Respiratory Tract Infections.
Pagina: https://europepmc.org/article/MED/40700358 — https://doi.org/10.1371/journal.pone.0317065. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-06T09:43:20.312Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.